innjoInnovaInnova2500-2937КГМУinnjo-263Research ArticleОБЗОРЫREVIEWSХимиотерапия онкологических заболеваний и риск развития кардиотоксического профиля на примере человеческого рекомбинированного моноклонального антитела бевацизумабCHEMOTHERAPY FOR ONCOLOGICAL DISEASES AND THE RISK OF DEVELOPING A CARDIOTOXIC PROFILE ON THE EXAMPLE OF THE HUMAN RECOMBINED MONOCLONAL ANTIBODY BEVACIZUMABhttps://orcid.org/0000-0001-8985-9599ХлямовСтанислав ВалерьевичKhlyamovStanislav Valerievich

Кафедра фармакологии, аспирант

Department of Pharmacology, Postgraduate Student

khlyamovsv@kursksmu.nethttps://orcid.org/0000-0003-1712-5005МальГалина СергеевнаMalGalina Sergeevna

Кафедра фармакологии, заведующий кафедрой фармакологии, профессор, доктор медицинских наук

Department of Pharmacology, Head of the Department of Pharmacology, Professor, Doctor of Medical Sciences

mgalina.2013@mail.ruhttps://orcid.org/0000-0003-3777-6622АртюшковаЕлена БорисовнаArtyushkovaElena Borisovna

Кафедра фармакологии, директор НИИ Экспериментальной медицины, доктор биологических наук, доцент

Department of Pharmacology, Director of the Research Institute of Experimental Medicine, Associate Professor, Doctor of Biological Sciences

eartyushkova@mail.ruhttps://orcid.org/0000-0003-3627-9747ГладченкоМихаил ПетровичGladchenkoMikhail Petrovich

НИИ Экспериментальной медицины, старший научный сотрудник, кандидат фармацевтических наук

Research Institute of Experimental Medicine, Senior Researcher, Candidate of Pharmaceutical Sciences

gladchenkomp@kursksmu.netФГБОУ ВО "Курский государственный медицинский университет" Минздрава РФРоссияKursk State Medical UniversityRussian Federation20232403202391Опубликован 30 марта 2023263Copyright © Хлямов С.В., Маль Г.С., Артюшкова Е.Б., Гладченко М.П., 20232023Хлямов С.В., Маль Г.С., Артюшкова Е.Б., Гладченко М.П.Khlyamov S.V., Mal G.S., Artyushkova E.B., Gladchenko M.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innova-journal.ru/jour/article/view/263

Выявление и лечение, связанной с химиотерапией онкологических нозологий, сердечно-сосудистой токсичности, определяемой либо как острое сердечное событие, либо как хроническое состояние, были тесно интегрированы в рутинную онкологическую помощь и стали важным компонентом при выборе лечения. Некоторые химиотерапевтические агенты, такие как антрациклины, традиционно характеризуются как кардиотоксические, но сердечно-сосудистые побочные эффекты также связаны с широко используемыми молекулярными таргетными препаратами. В последнее десятилетие бевацизумаб, моноклональное гуманизированное антитело против фактора роста эндотелия сосудов, был внедрен в лечение различных метастатических злокачественных новообразований. Несмотря на свою эффективность, бевацизумаб был связан со значительным риском сердечно-сосудистых осложнений, таких как артериальная гипертензия, ишемия сердца и застойная сердечная недостаточность. Основное внимание будет уделено токсичности бевацизумаба для сердечно-сосудистой системы с предоставлением последних данных о заболеваемости, клиническом спектре, факторах риска и ответственных механизмах.

The detection and management of chemotherapy-associated oncological nosologies, cardiovascular toxicity, defined as either an acute cardiac event or a chronic condition, has been tightly integrated into routine oncology care and has become an important component in treatment selection. Some chemotherapeutic agents, such as anthracyclines, are traditionally characterized as cardiotoxic, but cardiovascular side effects are also associated with commonly used molecular targeted drugs. In the last decade, bevacizumab, a monoclonal humanized antibody against vascular endothelial growth factor, has been introduced in the treatment of various metastatic malignancies. Despite its efficacy, bevacizumab has been associated with a significant risk of cardiovascular events such as hypertension, cardiac ischemia, and congestive heart failure. The focus will be on the cardiovascular toxicity of bevacizumab, with the latest data on incidence, clinical spectrum, risk factors, and responsible mechanisms provided.

бевацизумабсердечно-сосудистая токсичностьартериальная гипертензиякардиоонкологияbevacizumabcardiovascular toxicityarterial hypertensioncardiooncologyReferencesСердечно-сосудистые осложнения противоопухолевой терапии: диагностика, профилактика, лечение / под ред. И.Е. Чазовой, М.В. Вицени, Ф.Т. Агеева. - М.: ГРАНАТ, 2019. - 160 с.Cardiovascular complications of anticancer therapy: diagnosis, prevention, treatment / ed. I.E. Chazovoi, M.V. Viceni, F.T. Ageeva. - M.: GRANAT, 2019. - 160 p.Чазова И.Е., Агеев Ф.Т., Аксенова А.В. [и др.] Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022) // Евразийский Кардиологический Журнал. - 2022. - №1. - С. 6-79.Chazova I.E., Ageev F.T., Aksenova A.V. [et al.] Eurasian Clinical Guidelines for the Diagnosis, Prevention and Treatment of Cardiovascular Complications in Anticancer Therapy (2022) // Eurasian Journal of Cardiology. - 2022. - No. 1. - P. 6-79.Curigliano G., Lenihan D., Fradley M. [et al.] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations // Annals of Oncology. - 2020. - Vol. 31. - № 2. - P. 171-190.Curigliano G., Lenihan D., Fradley M. [et al.] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations // Annals of Oncology. - 2020. - Vol. 31. - № 2. - P. 171-190.Dedong Cao, Yongfa Zheng, Huilin Xu [et al.] Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis // Nature. - 2019. - № 9. - P. 1-8.Dedong Cao, Yongfa Zheng, Huilin Xu [et al.] Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis // Nature. - 2019. - № 9. - P. 1-8.Dent F.S. Practical cardio-oncology / F.S. Dent. - CRC Press, 2020. - 261 p.Dent F.S. Practical cardio-oncology / F.S. Dent. - CRC Press, 2020. - 261 p.Dobbin S.J.H., Mangion K., Berry C. [et al.] Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer // European Journal Heart Failure. - 2020. - №22. - P. 1276–1277.Dobbin S.J.H., Mangion K., Berry C. [et al.] Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer // European Journal Heart Failure. - 2020. - №22. - P. 1276–1277.Gilchrist S.C., Barac A., Ades P.A. [et al.] Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association // Circulation. - 2019. - №139. P. e997–e1012.Gilchrist S.C., Barac A., Ades P.A. [et al.] Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association // Circulation. - 2019. - №139. P. e997–e1012.Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia // Nature Reviews Cardiology. - 2020. - №17. - P. 474–502.Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia // Nature Reviews Cardiology. - 2020. - №17. - P. 474–502.Herrmann J. Vascular toxic effects of cancer therapies // Nature Reviews Cardiology. - 2020. - №17. - P. 503–522.Herrmann J. Vascular toxic effects of cancer therapies // Nature Reviews Cardiology. - 2020. - №17. - P. 503–522.Herrmann J., Lenihan D., Armenian S. [et al.] Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement // European Heart Journal. - 2022. - №43. - P. 280-299.Herrmann J., Lenihan D., Armenian S. [et al.] Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement // European Heart Journal. - 2022. - №43. - P. 280-299.Lancellotti P., Suter T.M., López-Fernández T. [et al.] Cardio-oncology services: rationale, organization, and implementation // European Heart Journal. - 2019. - №40. - P. 1756–1763.Lancellotti P., Suter T.M., López-Fernández T. [et al.] Cardio-oncology services: rationale, organization, and implementation // European Heart Journal. - 2019. - №40. - P. 1756–1763.Li M., Kroetz D.L. Bevacizumab-induced hypertension: clinical presentation and molecular understanding // Pharmacology & Therapeutics. - 2018. - Vol. 182. - № 2. - P. 152-160.Li M., Kroetz D.L. Bevacizumab-induced hypertension: clinical presentation and molecular understanding // Pharmacology & Therapeutics. - 2018. - Vol. 182. - № 2. - P. 152-160.Lyon A.R., Dent S., Stanway S. [et al.] Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society // European Journal Heart Failure. - 2020. - №22. - P. 1945–1960.Lyon A.R., Dent S., Stanway S. [et al.] Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society // European Journal Heart Failure. - 2020. - №22. - P. 1945–1960.Lyon A.R., López-Fernández T., Couch L.S. [et al.] 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) // European Heart Journal. - 2022. - №43(41). - P. 4229-4361.Lyon A.R., López-Fernández T., Couch L.S. [et al.] 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) // European Heart Journal. - 2022. - №43(41). - P. 4229-4361.Nhola L.F., Abdelmoneim S.S., Villarraga H.R. [et al.] Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers // Journal American Society Echocardiogrhy. - 2019. - №32. - P. 267–276.Nhola L.F., Abdelmoneim S.S., Villarraga H.R. [et al.] Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers // Journal American Society Echocardiogrhy. - 2019. - №32. - P. 267–276.Pandey A.K., Singhi E.K., Arroyo J.P. [et al.] Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease // Hypertension. - 2018. - №71. - P. E1–E8.Pandey A.K., Singhi E.K., Arroyo J.P. [et al.] Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease // Hypertension. - 2018. - №71. - P. E1–E8.Ran Xu, Chen Xu, Chuntong Liu [et al.] Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer // OncoTargets and Therapy. - 2018. - № 11. - P. 8605-8621.Ran Xu, Chen Xu, Chuntong Liu [et al.] Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer // OncoTargets and Therapy. - 2018. - № 11. - P. 8605-8621.

The authors declare that there are no conflicts of interest present.